You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A novel 3D cell culture human uterine contractility assay for high-throughput scr

    SBC: CHEMOSEN3D INC            Topic: NICHD

    DESCRIPTION (provided by applicant): Several disorders in reproductive medicine are results of changes in smooth muscle contractile activity. Increased myometrial contraction can lead to preterm labor, which affects 12% of the US population. However, the mechanisms involved in the transition from uterine quiescence to contractility at the onset of labor are not well-known. As a result, the managem ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Protein Bound RNA Sequencing

    SBC: BIOO SCIENTIFIC CORPORATION            Topic: NHGRI

    DESCRIPTION (provided by applicant): Protein-RNA interactions make a profound contribution to the regulatory logic of post- transcriptional control of gene expression. Tools to decipher this intricate layer of molecular interactions on a global scale are coming to the forefront of molecular biology and genomics. The most wide spread methodology to examine interactions of RNA binding proteins (RBPs ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Multi-functional particles for stem cell isolation and expansion

    SBC: PROGENITEC INC            Topic: NIMH

    DESCRIPTION (provided by applicant): The objective of this STTR Phase I proposal is to develop novel multi-layer microparticles and demonstrate their feasibility to isolate and expand stem cells for medical research and therapeutic applications. In recentyears, stem cells have been used in a wide variety of applications, including cell- based therapies, drug screening, and models to understand the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Optimized lactoferrin for treatment of intracerebral hemorrhage

    SBC: Pharmareview Corporation            Topic: NINDS

    DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Ovarian cancer using novel nanoparticle formulations

    SBC: KIROMIC BIOPHARMA INC            Topic: 102

    DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Lead Compound Discovery from Engineered Analogs of Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occi ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy

    SBC: CBS THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide H S in colorectal cancer In specific the selective upregulation of cystathionine synthase CBS and the subsequent production of H S in colonic cancer cells serves as a pro survival factor by stimulating tumor cell bioenergetics ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government